Abstract Thalamic volume loss is known to be associated with clinical and cognitive disability in progressive multiple sclerosis (PMS). To investigate the treatment effect of ibudilast on thalamic atrophy more than 96 weeks in the phase 2 trial in progressive(MS Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in Multiple Sclerosis [SPRINT-MS]). A total of 231 participants were randomized to either ibudilast (n = 114) or placebo (n = 117).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Kristina
Contact Kristina, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack